Market Cap: $2.22B
AI
Agios Pharmaceuticals, Inc.
AGIO
NASDAQ (NASDAQ Global Select)USD
Market Cap: $2.22B
Agios Pharmaceuticals (Ticker: AGIO) announces a pivotal shift in its hematology portfolio, showcasing its commitment to focus on more promising drug candidates. The recent decision to discontinue the…
Agios Pharmaceuticals has made a significant decision regarding its development pipeline, announcing the suspension of its drug, tebapivat, for lower risk myelodysplastic syndromes. This action follow…
Agios Pharmaceuticals (Ticker: AGIO) is making significant strides in advancing its drug mitapivat, marketed as AQVESME, for treating rare hematologic diseases. The company recently submitted a supple…
Agios Pharmaceuticals (Ticker: AGIO) is making strides in the treatment of sickle cell disease with the submission of a supplemental New Drug Application (sNDA) for mitapivat. This oral pharmacologica…
Agios Pharmaceuticals receives significant encouragement from the FDA regarding its drug mitapivat, designed to treat sickle cell disease. This pivotal moment occurs after a pre-supplemental New Drug…
Agios Pharmaceuticals Advances Regulatory Pathway for Mitapivat Agios Pharmaceuticals is making notable strides in the regulatory journey for mitapivat, an oral pyruvate kinase activator aimed at trea…
Agios Pharmaceuticals Faces Scrutiny Over Phase 3 Trial Results Agios Pharmaceuticals, a biopharmaceutical company known for its innovative approaches to treating rare diseases, finds itself under inv…
Investigation into Agios Pharmaceuticals Sparks Legal Action Among Shareholders In a notable development for Agios Pharmaceuticals, The Gross Law Firm has initiated an investigation into potential sec…
### Agios Pharmaceuticals Under Scrutiny Following Disappointing Clinical Results Agios Pharmaceuticals, a prominent player in the biopharmaceutical sector, finds itself under investigation due to its…
Agios Pharmaceuticals Faces Legal Scrutiny Over RISE UP Trial Results Agios Pharmaceuticals, a notable player in the biotechnology sector, draws attention as Levi & Korsinsky LLP opens an investigatio…
Agios Pharmaceuticals Faces Legal Scrutiny Over Alleged Misleading Statements Agios Pharmaceuticals, a leader in the development of innovative therapies for cancer and rare diseases, finds itself unde…
Agios Pharmaceuticals Faces Legal Scrutiny Over Securities Fraud Claims Agios Pharmaceuticals, Inc. is under investigation by multiple law firms in response to allegations of potential securities frau…
Agios Pharmaceuticals Faces Legal Scrutiny Following Phase 3 Trial Outcomes Agios Pharmaceuticals finds itself under investigation by Levi & Korsinsky for potential violations of federal securities la…
Agios Pharmaceuticals Under Investigation for Potential Securities Fraud Agios Pharmaceuticals, a leader in developing novel therapies for genetically-defined diseases, finds itself at the center of a…
Agios Pharmaceuticals Under Scrutiny Amid Legal Investigations Agios Pharmaceuticals, renowned for its innovative therapies targeting rare diseases, faces increasing scrutiny following two separate in…
Agios Pharmaceuticals Secures FDA Approval for Aqvesme, a Breakthrough Treatment for Thalassemia Agios Pharmaceuticals, Inc. recently receives a significant boost in its mission to address rare blood…
Agios Pharmaceuticals Secures FDA Approval for Aqvesme: A New Hope for Thalassemia Patients Agios Pharmaceuticals, Inc. has achieved a significant milestone with the recent approval from the U.S. Food…
Agios Pharmaceuticals Faces Setback with Mitapivat Trial Results Agios Pharmaceuticals Inc. is currently grappling with a significant setback following the disappointing topline results from the RISE…
Agios Pharmaceuticals Faces Challenges Amid RISE UP Trial Results Agios Pharmaceuticals Inc. encounters significant hurdles following the recent topline results from the RISE UP Phase 3 trial of mitap…
Sarepta's Upcoming Earnings Report: A Crucial Moment for Gene Therapy Innovation As Sarepta Therapeutics prepares to release its quarterly earnings report on November 3, 2025, the biotechnology indust…
Agios Pharmaceuticals: Focusing on Biopharmaceutical Innovations Amid Economic Challenges Agios Pharmaceuticals is at the forefront of biopharmaceutical development, particularly in the field of rare…
Agios Pharmaceuticals Prepares for Earnings Announcement Amid Product Pipeline Developments Agios Pharmaceuticals is gearing up to announce its quarterly earnings on October 30, 2025, a date that hold…
Agios Pharmaceuticals Prepares for Earnings Call Amidst Focus on Precision Medicine Agios Pharmaceuticals is gearing up to announce its quarterly earnings on October 30, 2025, with keen attention from…
Agios Pharmaceuticals Faces Legal Scrutiny Over Drug Application Disclosures Agios Pharmaceuticals, a biotech company known for developing innovative therapies for rare diseases, is currently under in…
Agios Pharmaceuticals Faces Extended Review for Pyrukynd in Thalassemia Treatment Agios Pharmaceuticals, Inc. is currently navigating an extended review period for its supplemental New Drug Applicatio…